- Everlight Chemical Industrial Corporation
- Industrial Technology Investment Corporation
- GIT Consultants Corporation
- SinoPac Venture Capital Corp.
- Other private investors
Since the inception of Andros Pharma, Dr. Wang led a team of researchers from diverse backgrounds of pharmacy, chemistry, chemical engineering, and molecular biology, to create the core competency of Andros Pharma. Consultants including medical physicians, professors, and lawyers, play important roles in forming strategies in R&D and business development.
Ae-June Wang , President and CEO
Dr. Ae-June Wang founded Andros Pharmaceuticals in 2008, and has been President and CEO since. Prior to Andros Pharma, she served as Vice President and Chief Science Officer at Purzer Pharmaceutical. She developed a topical liposomal product, first ever new dosage form approved in Taiwan. Before Purzer, she served as Senior Manager of Drug Delivery Department at ITRI, managing the GMP plant for transdermal patches. During her time at ITRI, she developed various innovative drug delivery technologies, which were subsequently transferred to domestic and foreign partners. Dr. Wang has over 50 patents, received numerous domestic and international awards, and has over 20 years of experience in drug development and management.
Dr. Wang received Ph.D. in Analytical Biochemistry from the University of Iowa, and conducted postdoctoral research at the University of Hawaii. She received B.S. in Chemistry from Fu Jen Catholic University.
Mei-Wen Yen, Director of Research and Development
Dr. Mei-Wen Yen joined Andros Pharma in 2014 as the Director of Research and Development. Prior to Andros Pharma, she served as a Senior Manager at Dow Pharmaceutical Sciences, where she led the development of topical new drugs. Before joining Dow Pharmaceutical, She served as Principal Scientist at Altana, Nycomed, and Fougera, with extensive experience in drug analysis, formulation and process development. Before entering pharmaceutical industry, she was an Assistant Professor in Chemistry at Fordham University. Dr. Yen has over 20 years of experience in the development of new dosage form and generic drugs.
Dr. Yen received Ph.D. in Chemistry from State University of New York (SUNY) at Stony Brook and B.S. in Chemistry from National Taiwan Normal University.
Shu-Min Ni, Director of Administration
Ms. Shu-Min Ni joined Andros Pharma in 2012. She has been serving as Assistant Manager, Manager, Senior Manager and Deputy Director of Finance and was recently promoted to Director of Administration. Prior to Andros Pharma, she served as Deputy Chief of Accounting at Shin-Etsu Handotai Taiwan. Before that, at an accounting firm, she was in charge of companies’ public offering and listing. Ms. Ni has over 18 years of experience in financial accounting, auditing, and administration.
Ms. Ni received B.S. of Accountancy from Chinese Cultural University.
Chen-Yu Huang, Deputy Director of Quality Management
Ms. Huang joined Andros Pharma in 2020 as the deputy director of Quality Management. She served as the Director of Quality Assurance at Sunny Pharmtech, Senior Manager of Quality Assurance at AUPA Biopharm and Manager of Quality Assurance at UBI Pharma. She has over 20 years of experience in quality management. She is knowledgeable on the Six subsystems of a Pharmaceutical Quality System, with ample experience in GMP inspection and familiar to PIC/S GMP related regulations and management.
Ms. Huang received M.S. in Chemical Engineering & Materials Science from Yuan Ze University and B.S. in Food Science from National Chiayi College.